Clinical Study of Hepatocyte Transplantation for Liver Cirrhosis

Status Not yet recruiting

Clinical Trial Summary

The Primary Objective: To observe and determine the safety and tolerance of allogeneic hepatocyte transplantation in patients with liver cirrhosis and to establish the maximum-tolerated dose (MTD) and evaluate the dose-limiting toxicities (DLTs). The Secondary Objective: To observe the therapeutic efficacy of allogeneic hepatocyte transplantation for liver cirrhosis.

Clinical Trial Description

- A traditional 3 + 3 dose escalation design will be implemented. - Successive cohorts of participants (3 or 3+3 participants /cohort) will start on a fixed cell numbers of allogeneic hepatocyte in three cohorts separately: L dose (low cell numbers); M dose (medium cell numbers); H dose (high cell numbers). - The 1st cohort will be given dose of L. - The 2nd cohort will be given dose of M. - The 3rd cohort will be given dose of H. - Dose escalation will continue until the maximum-tolerated dose (MTD). If no DLTs are observed for 28days after administration of the last dose, a new cohort will be enrolled at the next planned dose level. If DLTs are observed in 2 of the three participants, the MTD will be determined to be the dose administered to the previous cohort. If DLTs are observed in one participant in the cohort, another three participants will be treated with the same dose level. If the new three participants aren't observed DLTs, another cohort will be enrolled at the upper dose. If at least one of the new three ones are observed DLTs, the below dose will be the MTD. - MTD will stopped by testing increasing up to the H dose. - Toxicities will be graded using the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04806581
Study type	Interventional
Source	RenJi Hospital
Contact	Qiang Xia, Doctor
Phone	0086-02168383134
Email	xiaqiang@medmail.com.cn
Status	Not yet recruiting
Phase	Phase 1
Start date	April 20, 2021
Completion date	March 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04533932` - Endosonographic Shear Wave Elastography for Liver Stiffness
Not yet recruiting	`NCT06031740` - A Comparison of Flexible Endoscopic Polidocanol Liquid and Foam Sclerotherapy in Cirrhotic Patients With Bleeding From Internal Hemorrhoids	N/A
Not yet recruiting	`NCT06026267` - Efficacy of Conventional Dose Protocol vs Low Dose Protocol Albumin Use in Patients With Cirrhosis and High Risk Spontaneous Bacterial Peritonitis	N/A
Not yet recruiting	`NCT06076330` - Efficacy of 5% Albumin v/s Plasmalyte in Combination With 20% Albumin for Fluid Resuscitation in Cirrhosis With Sepsis Induced Hypotension	N/A
Enrolling by invitation	`NCT05055713` - A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism	N/A
Recruiting	`NCT04578301` - Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
Not yet recruiting	`NCT05515861` - Evaluation of EUS in Preventing Rebleeding After Endoscopic Cyanoacrylate Injection for Gastric Varices	N/A
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Not yet recruiting	`NCT03623360` - Functional MRI to Determine Severity of Cirrhosis
Not yet recruiting	`NCT02710227` - Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis	N/A
Completed	`NCT02917408` - Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Active, not recruiting	`NCT02551250` - Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis
Recruiting	`NCT02239991` - Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant	N/A
Enrolling by invitation	`NCT02256514` - Open Label Trial of Immunotherapy for Advanced Liver Cancer	Phase 2
Terminated	`NCT02311985` - Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics: A Randomized Clinical Trial	N/A
Terminated	`NCT01937130` - Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF	Phase 2
Recruiting	`NCT01618890` - Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding	Phase 3
Recruiting	`NCT01728688` - Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2
Recruiting	`NCT01724697` - Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2
Recruiting	`NCT01728727` - Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis	Phase 1/Phase 2